A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
Sabrina Rossi,Giovanna Finocchiaro,Vincenzo Di Noia,Maria Bonomi,Eleonora Cerchiaro,Fiorenza De Rose,Davide Franceschini,Pierina Navarria,Giovanni Luca Ceresoli,Giordano D. Beretta,Ettore D'Argento,Marta Scorsetti,Armando Santoro,Luca Toschi +13 more
TL;DR: TKI beyond progression in association with local ablative treatment is a valid treatment option in oligoprogressive patients with EGFR-mutated non-small-cell lung cancer.
Journal ArticleDOI
Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers
Francesco Zaja,Stefano De Luca,Umberto Vitolo,Lorella Orsucci,Alessandro Levis,Flavia Salvi,C. Rusconi,Erika Ravelli,Alessandra Tucci,Chiara Bottelli,Monica Balzarotti,Armando Santoro,Ercole Brusamolino,Maurizio Bonfichi,Alice Di Rocco,Caterina Stelitano,Luca Baldini,Stefano Pileri,Stefano Volpetti,Fabio Saccona,G. Ciccone,Antonella Ferranti,Ivana Catacchio,Roberto Ria,Angelo Vacca,Renato Fanin +25 more
TL;DR: The high therapeutic activity of Len in association with Dex in patients with relapsed and refractory MCL is confirmed with a favourable safety profile and the significant increase of the macrophage infiltration in the BM seems to be a possible immunomodulatory effect of Len.
Journal ArticleDOI
Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.
Michael Bitzer,Tom M. Ganten,M. A. Woerns,Jens T. Siveke,Matthias M. Dollinger,Max E. Scheulen,Henning Wege,Edoardo G. Giannini,Umberto Cillo,Franco Trevisani,Armando Santoro,Vincenzo Montesarchio,A. Mais,B. Hauns,Julia Asche,Thomas Herz,Stefano Pegoraro,Aldo Ammendola,Stefan W. Henning,Bernd Hentsch +19 more
TL;DR: A small number of patients in the phase I/II SHELTER study demonstrated efficacy and safety of the novel pan-HDAC inhibitor resminostat in second-line treatment of HCC patients and the drug was transferred to the clinic for further studies.
Journal Article
Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group.
J Buesa,H T Mouridsen,Armando Santoro,Riet Somers,Vivien H.C. Bramwell,A. van Oosterom,T. Wagener,C. P. J. Vendrik,D. Thomas +8 more
Journal ArticleDOI
High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin
Massimo Magagnoli,Giovanna Masci,Luca Castagna,Stefania Bramanti,Emanuela Morenghi,Carlo Carnaghi,Armando Santoro +6 more
TL;DR: Imported infections in east Birmingham children and increasing falciparum malaria in southwest London: a 25 year observational study.